EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer

Ying He, Aili Zhai, Kaiyun Qin, Xin Zhou, Yu Yu, Zhengmao Zhang

Discover Oncology · 29.08.2024 · 15 (1)

DOI: 10.1007/s12672-024-01267-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 29.08.2024. Verfasst von Ying He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The current research aims to evaluate the efficacy and safety of anlotinib, an orally administered small-molecular tyrosine kinase inhibitor (TKI), in the treatment of recurrent epithelial ovarian cancer (EOC). METHODS: Patients with recurrent EOC subjected to treatment with anlotinib in Fourth Hospital of Hebei Medical University from 2020 to 2022 were included. The evaluation involved a thorough review of medical records, focusing on parameters such as the objective response rate (ORR), disease control rate (DCR), survival outcomes, and safety profile. RESULTS: This study recorded 51 patients, with 26 patients undergoing anlotinib monotherapy. The median progression-free survival (PFS) was 4.0 months, whereas the median overall survival (OS) was not reached. Seven cases underwent a combined treatment of anlotinib with chemotherapy. Among them, two patients achieved partial response (PR), two were categorized as stable disease (SD), and three were identified as having progressive disease (PD). The ORR and DCR were 28.5% (2/7) and 57.1% (4/7), respectively. Additionally, 18 cases received anlotinib maintenance therapy, and the median PFS and the median OS were 7.0 months and 25.5 months, respectively. The most prevalent adverse effects included fatigue (38.6%), hypertension (27.3%), nausea and vomiting (25.0%) and hand-foot syndrome (25.0%). CONCLUSION: Anlotinib demonstrated mild efficacy in the treatment of recurrent EOC, whether employed as monotherapy, chemotherapy-combined therapy, or maintenance therapy. The safety profile was proven manageable and well-tolerated, suggesting that anlotinib may emerge as a viable and novel treatment option for recurrent EOC.

Schlagwörter

Stichwörter der Autor:innen

AnlotinibDCRORRRecurrent epithelial ovarian cancerSurvival

Autor:innen und Institutionen

  • Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
  • Department of Gynecology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000, Hebei, China.
  • Department of Gynecology, Bao Ding No.1 Central Hospital, Baoding, 071000, Hebei , China.
  • Department of Gynecology, Hebei General Hospital, Shijiazhuang, 050000, Hebei, China.
  • Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China. zhangzhengmao@hbmu.edu.

Zitieren

APA

He, Y., Zhai, A., Qin, K., Zhou, X., Yu, Y., & Zhang, Z. (2024). Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-01267-8

Vancouver

He Y, Zhai A, Qin K, Zhou X, Yu Y, Zhang Z. Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-01267-8

BibTeX
@article{He2024,
  author = {He, Ying and Zhai, Aili and Qin, Kaiyun and Zhou, Xin and Yu, Yu and Zhang, Zhengmao},
  title = {Assessment of the efficacy and safety of anlotinib for the treatment of recurrent epithelial ovarian cancer},
  journal = {Discover Oncology},
  year = {2024},
  volume = {15},
  number = {1},
  doi = {10.1007/s12672-024-01267-8}
}
Kostenlos starten →